To empirically and functionally validate our network pharmacology and molecular docking predictions, we used RT-qPCR analysis on four target genes; 2 genes (AKT1 and EGFR) identified as top hub genes and tested by molecular docking (binding affinity ≤ −6 kcal/mol) and 2 genes (TP53 and CASP3) selected for their canonical role in cancer development and progression. This evidence concerns the gene EGFR and cancer.